GET DAILY SIGNALSCompass Therapeutics (CMPX): What Investors Should Watch in Q3 2026 Earnings
Key Takeaways
- Wall Street expects a net loss of roughly $0.12 to $0.13 per share for the third quarter of 2026, compared with a loss of $0.08 per share in the same period a year earlier.
- Consensus revenue is minimal—around $0.23 million—consistent with Compass Therapeutics' status as a pre-revenue, clinical-stage biotech.
- The company reported a loss of $0.13 per share in the second quarter of 2026, missing the $0.11 consensus estimate, and has beaten EPS estimates in three of its last eight quarters.
- With no product sales, investors are watching cash position, R&D spending, and clinical milestones for tovecimig and CTX-8371.
- Analysts maintain a consensus "Moderate Buy" rating, though price targets span a wide range.
- For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast pages.
- Discover actionable market ideas with Trending AI Robots.
Earnings Context and Why It Matters
Compass Therapeutics, Inc. (CMPX) is a Boston-based, oncology-focused biopharmaceutical company developing antibody-based therapies, and it currently generates essentially no product revenue. That makes its quarterly earnings release less about top-line sales and more about two things: how quickly it is burning cash and how its clinical pipeline is advancing. The company's lead candidate, tovecimig (a DLL4 x VEGF-A bispecific antibody), reported positive Phase 2/3 data earlier in 2026 in biliary tract cancer, while CTX-8371 (a PD-1 x PD-L1 bispecific antibody) is advancing through early-stage studies. For investors, the Q3 2026 report is a checkpoint on spending discipline, cash runway, and management's updated clinical timeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
Compass Therapeutics is expected to report results for the third quarter of 2026, the three-month period ended September 30, 2026. The company follows a standard calendar fiscal year. Consensus estimates point to a net loss of approximately $0.12 to $0.13 per share, with revenue of roughly $0.23 million. In the year-ago quarter, the company posted a narrower loss of $0.08 per share, so analysts are modeling a wider loss on a year-over-year basis.
Recent history shows a mixed track record. In the second quarter of 2026, Compass reported a loss of $0.13 per share, missing the $0.11 consensus estimate by $0.02. For the full year 2026, analysts currently project a loss of about $0.47 to $0.48 per share, with a similar loss of roughly $0.49 to $0.52 expected in 2027. Because the company is pre-revenue, the headline EPS figure matters less than the balance-sheet metrics investors will scrutinize: cash and investments on hand, quarterly R&D and general spending, and any updated runway commentary.
Market Reaction and Investor Sentiment
Sentiment heading into the third-quarter 2026 report has been shaped less by the earnings print itself and more by clinical catalysts and financing concerns. Shares pulled back sharply from their 52-week high earlier in 2026, and the stock has traded well below those levels in recent weeks. For a pre-revenue biotech, the market's reaction to an earnings release is often muted compared with the swings triggered by data readouts. Key risk factors include the pace of cash consumption, the potential for additional equity offerings, and any changes to the timing of the tovecimig and CTX-8371 programs. Investors will also weigh whether the company reaffirms its stated cash runway, which management and analysts have previously described as extending into 2027 or 2028.
Forward Outlook and Key Factors to Monitor
Looking beyond the third-quarter report, the most important variables for Compass Therapeutics are clinical and operational rather than purely financial. Investors should watch for updated guidance on the cash runway and any commentary on spending trajectory, since the company remains unprofitable and dependent on its cash reserves to fund development.
The tovecimig program in biliary tract cancer is the central near-term catalyst. After reporting statistically significant progression-free survival improvements earlier in 2026, the company has been expected to advance toward a potential Biologics License Application, the formal request for regulatory approval. The timing and scope of that submission will be closely watched.
Separately, the CTX-8371 bispecific antibody is enrolling expansion cohorts in several tumor types, and additional early-stage data could shape sentiment. Investors should also monitor R&D expense trends, any changes to collaboration or financing plans, and the broader oncology-funding environment. As always, these factors carry meaningful uncertainty, and clinical or regulatory setbacks could materially affect the outlook. From what I see, this is important because the next few quarters will test the company's execution on both the financial and clinical fronts.
Exploring Biotech Opportunities with Tickeron Tools
In my analysis of pre-revenue biotechs like Compass Therapeutics, I often turn to Tickeron’s AI Screener to quickly filter names by sector, cash metrics, and upcoming catalysts. It has helped me surface comparable companies and spot patterns ahead of earnings without manually sifting through dozens of filings. The tool also lets me cross-check technical signals and volatility trends, which adds useful context when clinical timelines are the real driver of value.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CMPX in -4.26% downward trend, sliding for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where CMPX declined for three days, in 268 of 305 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 19, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CMPX as a result. In 73 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Aroon Indicator for CMPX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for CMPX just turned positive on October 09, 2026. Looking at past instances where CMPX's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +1.75% 3-day Advance, the price is estimated to grow further. Considering data from situations where CMPX advanced for three days, in 230 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.827) is normal, around the industry mean (3.051). P/E Ratio (-1.956) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (555.556) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. CMPX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CMPX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement